Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4188.40 +0.4% SILVER 57.15 −0.0% COPPER 6.56 +0.1% OIL 98.94 +1.0% PALLADIUM 1115.50 −1.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% GOLD 4188.40 +0.4% SILVER 57.15 −0.0% COPPER 6.56 +0.1% OIL 98.94 +1.0% PALLADIUM 1115.50 −1.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5%

Healthcare

Page 63
  1. Feb 10, 2026 · 07:30 · HELP

    Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

    Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

    01
  2. Feb 10, 2026 · 07:28 · CRDL

    Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

    Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

    02
  3. Feb 10, 2026 · 07:01 · TLT

    Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting

    Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting

    03
  4. Feb 10, 2026 · 07:01 · THRM

    Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial

    Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial

    04
  5. Feb 10, 2026 · 03:01 · VIVI

    TempraMed Partners with Super-Pharm, Israel's Leading Pharmacy Chain to Commence a National Product Roll Out Strategy

    TempraMed Partners with Super-Pharm, Israel's Leading Pharmacy Chain to Commence a National Product Roll Out Strategy

    05
  6. Feb 09, 2026 · 17:54 · RX

    BioSyent to acquire Oral Science for $25.5-million

    BioSyent to acquire Oral Science for $25.5-million

    06
  7. Feb 09, 2026 · 17:00 · MSCL

    Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares

    Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares

    07
  8. Feb 09, 2026 · 07:30 · RX

    BioSyent to Acquire Oral Science Inc.

    BioSyent to Acquire Oral Science Inc.

    08
  9. Feb 09, 2026 · 07:28 · ARCH

    Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

    Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

    09
  10. Feb 09, 2026 · 07:03 · VITA

    Vitalist and MicroEJ Partner with BENIO to Launch First VitalOS(TM) Powered Smartwatch in Asia

    Vitalist and MicroEJ Partner with BENIO to Launch First VitalOS(TM) Powered Smartwatch in Asia

    10
  11. Feb 09, 2026 · 07:01 · CHER

    Cheelcare Announces $1.0 Million Unsecured Note Financing

    Cheelcare Announces $1.0 Million Unsecured Note Financing

    11
  12. Feb 09, 2026 · 07:00 · NGEN

    NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

    NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

    12
  13. Feb 09, 2026 · 07:00 · ZYUS

    ZYUS Life Sciences Announces Filing of Amended and Restated LIFE Offering Document

    ZYUS Life Sciences Announces Filing of Amended and Restated LIFE Offering Document

    13
  14. Feb 09, 2026 · 03:01 · PREV

    PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents

    PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents

    14
← Newer Older →